The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease
Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;
The average VAS score of pain in the week before enrollment is ≥4;
The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);
Women aged 18 to 50 (including 18 and 50) with a history of sexual life;
Pelvic inflammatory disease (acute attack);
Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;
Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;
Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;